Impact Factor 3.845 | CiteScore 3.92
More on impact ›

Correction ARTICLE

Front. Pharmacol., 15 November 2019 | https://doi.org/10.3389/fphar.2019.01358

Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis

Shuang Dai1,2,3†, Yuanliang Yan1,3†, Zhijie Xu1,3,4, Shuangshuang Zeng1,3, Long Qian1,3, Lei Huo5, Xuejun Li5, Lunquan Sun6 and Zhicheng Gong1,3*
  • 1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
  • 2School of Pharmaceutical Sciences, Central South University, Changsha, China
  • 3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
  • 4Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
  • 5Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
  • 6Center for Molecular Medicine, Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China

A Corrigendum on
SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis.

By Dai S, Yan Y, Xu Z, Zeng S, Qian L, Huo L, Li X, Sun L and Gong Z (2018) Front. Pharmacol. 8:960. doi: 10.3389/fphar.2017.00960

In the original article, there was a mistake in Figure 6D as published. The final submission for the SCD1 bands in Figure 6D was inadvertently truncated too short. The corrected Figure 6D appears below.

FIGURE 6
www.frontiersin.org

Figure 6 Modulation of Akt activation level has a feedback effect on the SCD1 level. Western blot for phospho-Akt (Ser-473), Akt, phospho-GSK3b (Ser-9),GSK3β, β-catenin, and SCD1 in T98G and U87 cells treated with pcDNA3.1, pcDNA-SCD1, EGF or pcDNA-SCD1 plus EGF (A, B), or T98G-R and U87-R treated with DMSO, A939572, MK2206, A939572 plus MK2206, LY294002 and A939572 plus LY294002 (C, D). All western blots are representative of results from at least three independent experiments. And α-Tubulin was used as the internal control.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: glioblastomas, temozolomide, resistance, SCD1, Akt signaling

Citation: Dai S, Yan Y, Xu Z, Zeng S, Qian L, Huo L, Li X, Sun L and Gong Z (2019) Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis. Front. Pharmacol. 10:1358. doi: 10.3389/fphar.2019.01358

Received: 30 September 2019; Accepted: 28 October 2019;
Published: 15 November 2019.

Edited by:

Julie Gavard, Institut National de la Santé et de la Recherche Médicale (INSERM), France

Reviewed by:

Julie Gavard, Institut National de la Santé et de la Recherche Médicale (INSERM), France

Copyright © 2019 Dai, Yan, Xu, Zeng, Qian, Huo, Li, Sun and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhicheng Gong, gongzhicheng@csu.edu.cn

These authors have contributed equally to this work